单克隆抗体：治疗多发性骨髓瘤的最大资源。
Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.
机构信息
Department of Chemical, Biological, Pharmaceutical and Environmental Chemistry, University of Messina, Viale F. Stagno d'Alcontres 31, 98166 Messina, Italy.
Department of Human Pathology in Adulthood and Childhood, University of Messina, Via Consolare Valeria, 90100 Messina, Italy.
出版信息
Int J Mol Sci. 2023 Feb 5;24(4):3136. doi: 10.3390/ijms24043136.
Multiple myeloma (MM) is a currently incurable hematologic cancer. This disease is characterized by immunological alterations of myeloid cells and lymphocytes. The first-line therapy involves the use of classic chemotherapy; however, many patients have a relapsed form that could evolve into a refractory MM. The new therapeutic frontiers involve the use of new monoclonal antibodies (Mab) such as daratumumab, isatuximab, and elotuzumab. In addition to monoclonal antibodies, new immunotherapies based on modern bispecific antibodies and chimeric antigen receptor (CAR) T cell therapy have been investigated. For this reason, immunotherapy represents the greatest hope for the treatment of MM. This review intends to focus the attention on the new approved antibody targets. The most important are: CD38 (daratumumab and isatuximab), SLAM7 (elotuzumab), and BCMA (belantamab mafodotin) for the treatment of MM currently used in clinical practice. Although the disease is still incurable, the future perspective is to find the best therapeutic combination among all available drugs.
多发性骨髓瘤（MM）是一种目前无法治愈的血液系统癌症。这种疾病的特征是髓样细胞和淋巴细胞的免疫改变。一线治疗包括使用经典化疗；然而，许多患者存在复发形式，可能演变为难治性 MM。新的治疗前沿涉及使用新型单克隆抗体（Mab），如达雷妥尤单抗、伊沙妥昔单抗和埃罗妥珠单抗。除了单克隆抗体，还研究了基于现代双特异性抗体和嵌合抗原受体（CAR）T 细胞疗法的新免疫疗法。因此，免疫疗法是治疗 MM 的最大希望。本文旨在关注新批准的抗体靶点。最重要的是：目前在临床实践中用于治疗 MM 的 CD38（达雷妥尤单抗和伊沙妥昔单抗）、SLAM7（埃罗妥珠单抗）和 BCMA（贝兰他单抗mafodotin）。尽管这种疾病仍然无法治愈，但未来的前景是在所有可用药物中找到最佳的治疗组合。
Zotero 插件